Cosmos Health Inc. (NASDAQ:COSM) Short Interest Up 163.2% in June

Cosmos Health Inc. (NASDAQ:COSM) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totaling 2,343,632 shares, a growth of 163.2% from the May 31st total of 890,287 shares. Based on an average daily trading volume, of 14,830,375 shares, the days-to-cover ratio is presently 0.2 days. Currently, 5.1% of the company’s stock are sold short.

Cosmos Health Price Performance

Shares of NASDAQ COSM opened at $0.17 on Monday. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $10.69 million, a price-to-earnings ratio of -0.27 and a beta of 4.80. Cosmos Health has a twelve month low of $0.16 and a twelve month high of $1.32. The business has a 50 day simple moving average of $0.28 and a 200-day simple moving average of $0.37.

Cosmos Health (NASDAQ:COSM) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). The firm had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.93 million. Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%. As a group, equities research analysts expect that Cosmos Health will post -0.06 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cosmos Health in a research note on Monday, June 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Insider Buying and Selling

In related news, CFO Georgios Terzis purchased 168,135 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was acquired at an average price of $0.25 per share, for a total transaction of $42,033.75. Following the completion of the purchase, the chief financial officer owned 2,235,398 shares in the company, valued at approximately $558,849.50. This represents a 8.13% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Grigorios Siokas purchased 218,447 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $0.21 per share, for a total transaction of $45,873.87. Following the completion of the acquisition, the chief executive officer directly owned 13,481,808 shares of the company’s stock, valued at $2,831,179.68. This represents a 1.65% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 1,088,029 shares of company stock valued at $249,240 in the last three months. Corporate insiders own 26.15% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its position in shares of Cosmos Health by 260.5% during the 4th quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after buying an additional 241,775 shares during the last quarter. Citadel Advisors LLC lifted its holdings in Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after acquiring an additional 128,776 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after acquiring an additional 34,117 shares during the last quarter. 12.61% of the stock is currently owned by institutional investors.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.